Company / Current Liabilities
Avalo Therapeutics, Inc. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$12.9M
FY2025
5-year range
$4.6M / $22.1M
FY2021-FY2025
Trend
+85.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 9 years, ranging from $5M in FY2023 to $26M in FY2018.
Based on SEC 10-K filings.
$13M in FY2025 with a 5-year CAGR of -3.2%.
Increased from $5M to $13M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -16.4%
- 5-Year CAGR
- -3.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -3.2%, indicating a declining trend.
- In FY2025, current liabilities increased 85.9% year-over-year.
- Peak current liabilities was recorded in FY2018.
- Lowest current liabilities in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.9M | +85.9% |
| FY2024 | $7.0M | +50.7% |
| FY2023 | $4.6M | -79.1% |
| FY2022 | $22.1M | +11.2% |
| FY2021 | $19.9M | +30.6% |
| FY2020 | $15.2M | +25.2% |
| FY2019 | $12.2M | -53.6% |
| FY2018 | $26.2M | +136.4% |
| FY2017 | $11.1M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026